

20<sup>th</sup> July 2020

(1) BSE Ltd  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex, Bandra (East),  
Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

**Sub: Update on Cipla and Amgen reach a settlement on pending litigation involving generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg)**

Dear Sir / Madam,

This is to inform you that the civil action filed by Cipla Limited and Cipla USA Inc, wholly owned step-down subsidiary of Cipla Limited (hereinafter together referred to as "Cipla") in the U.S. District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc. (hereinafter referred to as "Amgen"). A formal stipulation of dismissal has been filed with the Court and is awaiting signature by the presiding Judge. Cipla's action pertaining to Teva Pharmaceuticals Inc. remains pending. The resolution entitles Cipla and its affiliates to continue importing, marketing, and selling its generic cinacalcet hydrochloride tablets 30mg, 60mg and 90mg in the United States.

Cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Kindly acknowledge the receipt.

This is for your information and records.

Thanking you,

**Yours faithfully,  
For Cipla Limited**

**Rajendra Chopra  
Company Secretary**

Prepared by: Juzer Masta